Hungarian Anavar??
- Thread starter westsider
- Start date
GetnBigr
New member
internet search revealed the following:
Chinoin Co., Ltd.
--------------------------------------------------------------------------------
Main products / technologies
Ø Prostaglandins
Ø Drotaverine (No-Spa)
Ø Selegiline Hydrochloride (Jumex, Eldepryl)
Company Profile
Founded
1910
Major Shareholders
Sanofi-Synthélabo Group (~99%)
Capital
4000 Million HUF
Number of Employees
Approx. 2000
Sales
N. A.
Quality Control
GMP
History, activities
Chinoin Pharmaceutical and Chemical Works Co., Ltd. - member of Sanofi-Synthelabo Group has been one of the leading players in the Hungarian pharmaceutical industry for almost a century.
Established in 1910, the company has been the powerhouse of innovations in the field of pharmaceutical chemistry, leading to over 1300 patents worldwide since its foundation.
Besides the process innovations, the most important original products developed by Chinoin are:
Homatropyne Methylbromide (already discontinued)
Drotaverine (No-Spa)
Selegiline Hydrochloride (Jumex, Eldepryl)
From 1991 until 1997, Sanofi, France successively acquired the ownership of Chinoin from the Hungarian State. In 1999 Sanofi merged with another French group, Synthélabo.
Today, the company has comprehensive activities in Hungary:
R&D as an integral part in Sanofi-Synthélabo research.
Chemical Development and Manufacturing of several active ingredients and key intermediates for group core products.
Pharmaceutical Development and Manufacturing of group products as well as the traditional Hungarian and East European portfolio.
Marketing and Sales arm of the group in Hungary.
East European Distribution Center.
Prostaglandin Unit.
The total synthesis of Prostaglandins has more than 30 years history in the company and now forms a unique, significant business. Chinoin is a world market leader in supplying almost all known active ingredients in this field, natural and modified Prostaglandins as well as Prostacycline derivatives.
Since the privatization in 1991, Sanofi-Synthélabo has spent over Euro 200 million on the modernization of the Hungarian affiliate, on capital expenditures that completely renewed Chinoin's research and development, the chemical and pharmaceutical facilities, including prostaglandin production and the infrastructure, neglected so much during the communist era. Particular attention and important material resources have been spent on the creation of environment protection activity satisfying the European norms.
In the meantime the research activities of the mother company has come to fruition for the beginning of 2000. Clinical studies of outstandingly high number of compounds, about 50 active ingredients has been carried and are carried at different places of the world, like in Hungary. Some compounds among them have become successful medicines since, such as Approvel®, an agent against hypertension and Plavix®, an agent against thrombosis.
One of the fastest growing pharmaceutical companies of the world, Sanofi-Synthélabo intends to spend further Euro 200 million on the development of Chinoin in the next three years. Thanks to the employees' professional skills, diligence and the level of added value, Chinoin is going to become a very important research and development center and chemical and pharmaceutical site of the Group in the near future.
Chinoin Co., Ltd.
--------------------------------------------------------------------------------
Main products / technologies
Ø Prostaglandins
Ø Drotaverine (No-Spa)
Ø Selegiline Hydrochloride (Jumex, Eldepryl)
Company Profile
Founded
1910
Major Shareholders
Sanofi-Synthélabo Group (~99%)
Capital
4000 Million HUF
Number of Employees
Approx. 2000
Sales
N. A.
Quality Control
GMP
History, activities
Chinoin Pharmaceutical and Chemical Works Co., Ltd. - member of Sanofi-Synthelabo Group has been one of the leading players in the Hungarian pharmaceutical industry for almost a century.
Established in 1910, the company has been the powerhouse of innovations in the field of pharmaceutical chemistry, leading to over 1300 patents worldwide since its foundation.
Besides the process innovations, the most important original products developed by Chinoin are:
Homatropyne Methylbromide (already discontinued)
Drotaverine (No-Spa)
Selegiline Hydrochloride (Jumex, Eldepryl)
From 1991 until 1997, Sanofi, France successively acquired the ownership of Chinoin from the Hungarian State. In 1999 Sanofi merged with another French group, Synthélabo.
Today, the company has comprehensive activities in Hungary:
R&D as an integral part in Sanofi-Synthélabo research.
Chemical Development and Manufacturing of several active ingredients and key intermediates for group core products.
Pharmaceutical Development and Manufacturing of group products as well as the traditional Hungarian and East European portfolio.
Marketing and Sales arm of the group in Hungary.
East European Distribution Center.
Prostaglandin Unit.
The total synthesis of Prostaglandins has more than 30 years history in the company and now forms a unique, significant business. Chinoin is a world market leader in supplying almost all known active ingredients in this field, natural and modified Prostaglandins as well as Prostacycline derivatives.
Since the privatization in 1991, Sanofi-Synthélabo has spent over Euro 200 million on the modernization of the Hungarian affiliate, on capital expenditures that completely renewed Chinoin's research and development, the chemical and pharmaceutical facilities, including prostaglandin production and the infrastructure, neglected so much during the communist era. Particular attention and important material resources have been spent on the creation of environment protection activity satisfying the European norms.
In the meantime the research activities of the mother company has come to fruition for the beginning of 2000. Clinical studies of outstandingly high number of compounds, about 50 active ingredients has been carried and are carried at different places of the world, like in Hungary. Some compounds among them have become successful medicines since, such as Approvel®, an agent against hypertension and Plavix®, an agent against thrombosis.
One of the fastest growing pharmaceutical companies of the world, Sanofi-Synthélabo intends to spend further Euro 200 million on the development of Chinoin in the next three years. Thanks to the employees' professional skills, diligence and the level of added value, Chinoin is going to become a very important research and development center and chemical and pharmaceutical site of the Group in the near future.
Similar threads
